- The independent Institutional Review Board has granted approval to AIM ImmunoTech (AIM +3.8%) to widen the trial for its drug candidate Ampligen and include people suffering from long-term effects of the coronavirus (COVID-19).
- The group, known as COVID-19 ‘long haulers’ as they continue to show chronic fatigue-like symptoms for months after officially recovering from their initial illness, will be included in the clinical trial for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
- Up to 20 of the 100 active participants can be long haulers, according to the new trial protocol amendment, and the firm is now preparing the IRB-approved protocol for submission to the FDA.
- In June, the company filed a provisional utility patent application for Ampligen to be used as a possible treatment for chronic fatigue associated with COVID-19.
- https://seekingalpha.com/news/3620182-aim-immunotech-to-recruit-long-term-covidminus-19-patients-chronic-fatigue-in-ampligen-trial
Tuesday, October 6, 2020
AIM ImmunoTech to recruit long-term Covid patients with chronic fatigue
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.